{"organizations": [], "uuid": "e91b75e1ab1f5a6791b3eab332eba4aefc9c8617", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/01/globe-newswire-zafgen-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2017-financial-results.html", "country": "US", "domain_rank": 767, "title": "Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-03-02T00:30:00.000+02:00", "replies_count": 0, "uuid": "e91b75e1ab1f5a6791b3eab332eba4aefc9c8617"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/01/globe-newswire-zafgen-to-host-conference-call-to-discuss-fourth-quarter-and-full-year-2017-financial-results.html", "ord_in_thread": 0, "title": "Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2017 Financial Results", "locations": [], "entities": {"persons": [{"name": "zafgen zafgen", "sentiment": "none"}], "locations": [{"name": "zafgen", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "BOSTON, March 01, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today that it will host a conference call on Tuesday, March 6, 2018 at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year ended December 31, 2017.\nParticipants may access the call by dialing (844) 824-7428 in the U.S. or (973) 500-2177 outside the U.S. and referencing conference ID number 7184949. The call will also be webcast live on the Company's website at https://zafgen.gcs-web.com/events-and-presentations . A replay of this conference call will be available beginning at 7:30 p.m. ET on March 6, 2018 through March 13, 2018 by dialing (855) 859-2056 in the U.S. or (404) 537-3406 outside the U.S. To access the replay please provide conference ID number 7184949.\nAbout Zafgen\nZafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of complex metabolic diseases. Zafgen has pioneered the study of MetAP2 inhibitors in both common and rare metabolic disorders, and its current disease areas of focus are type 2 diabetes, Prader-Willi syndrome and liver diseases. The companyâ€™s lead product candidate is ZGN-1061, a MetAP2 inhibitor in Phase 2 clinical development with unique properties that maximize impact on metabolic parameters relevant to the treatment of type 2 diabetes and other related metabolic disorders. In 2018, Zafgen plans to file an investigational new drug (IND) application with the U.S. FDA and initiate Phase 1 clinical trials for ZGN-1258, its new molecule for the treatment of Prader-Willi syndrome and potential other rare and serious forms of obesity. Learn more at www.zafgen.com .\nMedia/Investor Relations Contacts :\nZafgen, Inc.\nPatricia Allen\nChief Financial Officer\n617-648-9792\nMedia\nKrystle Gibbs\nTen Bridge Communications\nkrystle@tenbridgecommunications.com\n508-479-6358\nInvestors\nJohn Woolford\nWestwicke Partners\nJohn.woolford@westwicke.com\n443-213-0506\nSource:Zafgen, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=2fVWw9sGOwaMgaP6mu4Ghlo1xNCuwPD5VOpBqdWYucHus1Aiu4qF6awrziEYSkvVlfkMEGFfNWG3s8QwKgkI_AjYTXPa13eQq2kfOhkmlaPSmMy9h4IDtb6F7W79ZBWTXBz4gf-RnWuQKvg_AIOueV8agyWcnVbZUaVAEwZfdH0=", "https://www.globenewswire.com/NewsRoom/AttachmentNg/ee4d8e02-e39f-4e10-a617-f5bc5ec8aea6", "https://www.globenewswire.com/Tracker?data=9caVQtXVJGudnJvtoy4ujdWB6ciozu3Vm7wBb_mN8YlSbU2pB9XHJa_ZyKJK7_Gue33AIbBCzdd-E0pmpHDpQA==", "https://zafgen.gcs-web.com/events-and-presentations", "https://www.globenewswire.com/Tracker?data=qR-FGgvl05mXFWydvxDgv-A3CcYM4-3K--u3GCewqG3AV5he4hS_lr6PlSOg297l_XZeGIAhvgYnXyqVHeeFtscFgliLZw7nYAwwCUXrFwvpkwIPBTrEtdrJqQWzZkYJ", "https://www.globenewswire.com/Tracker?data=Nwj8nAh0WLrUrL4d-XYoeK3lF1-vSpxfN2wZBEs6p3lSPQDZaGdbd_PMiCP1_jEsRWrH7cEF6PH6wGMXDEMzXCaZNmi3eqwlJlAeO2tIjk_7DyRLdfVUCWeXrZdRhu4O-kpibWm47EhGW1cDwGM4mA=="], "published": "2018-03-02T00:30:00.000+02:00", "crawled": "2018-03-02T00:45:24.002+02:00", "highlightTitle": ""}